Research analysts who have asked questions during CollPlant Biotechnologies earnings calls.
BH
Ben Haynor
Lake Street Capital Markets
1 question for CLGN
Also covers: APYX, ATEC, BFLY +6 more
R
RK
HC Wainright
1 question for CLGN
Also covers: HOOK, MDWD
SP
Steve Perry
Airco Industries
1 question for CLGN
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
1 question for CLGN
Also covers: ABSI, BSEM, CGEN +24 more
Recent press releases and 8-K filings for CLGN.
CollPlant Biotechnologies Ltd. Announces $2.0 Million Registered Direct Offering
CLGN
- CollPlant Biotechnologies Ltd. entered into a securities purchase agreement on February 4, 2026, with institutional investors for a registered direct offering.
- The offering includes the sale of 1,600,000 ordinary shares at a purchase price of $1.25 per share, along with unregistered series A and series B warrants to purchase up to 1,600,000 ordinary shares each, both with an exercise price of $1.25 per share.
- The aggregate gross proceeds from the offering are expected to be approximately $2.0 million, excluding potential proceeds from future warrant exercises.
- The offering is expected to close on or about February 6, 2026, and the net proceeds will be used for general corporate purposes, including working capital and funding research and development programs.
19 hours ago
CollPlant Biotechnologies Announces $2.0 Million Registered Direct Offering
CLGN
New Projects/Investments
- CollPlant Biotechnologies announced a $2.0 million registered direct offering.
- The offering includes the issuance and sale of 1,600,000 ordinary shares at a purchase price of $1.25 per share.
- Concurrently, the company will issue unregistered series A and series B warrants, each to purchase up to 1,600,000 ordinary shares at an exercise price of $1.25 per share.
- The offering is expected to close on or about February 6, 2026.
- CollPlant intends to use the net proceeds for general corporate purposes, including working capital and funding its research and development programs.
2 days ago
CollPlant Biotechnologies Reports Q3 2025 Financial Results, Announces Cost Reductions, and Board Change
CLGN
Earnings
Layoffs
Board Change
- CollPlant Biotechnologies reported GAAP revenues of $2.3 million for the nine months ended September 30, 2025, primarily driven by a $2 million milestone payment from AbbVie. The GAAP net loss for Q3 2025 was $3.5 million (or $0.27 basic loss per share), an improvement compared to the prior year.
- As of September 30, 2025, cash and cash equivalents totaled $8.5 million, which includes $3.1 million in net proceeds from a registered direct offering in June 2025.
- The company has initiated a cost reduction and workforce reduction plan, anticipating a 25% reduction in its workforce, contributing to a decrease in operating expenses.
- The lead dermal filler candidate from the AbbVie collaboration is currently in the clinical phase, with AbbVie reviewing interim results. CollPlant is also expanding its rhCollagen and BioInk distribution in North America through a new logistics center.
- Roger Pomerantz, M.D., will not seek re-nomination as Board Chairman, and CEO Yehiel Tal has been nominated as interim Chairman.
Nov 26, 2025, 12:38 PM
CollPlant Biotechnologies Reports Q3 2025 Financial Results and Corporate Updates
CLGN
Earnings
New Projects/Investments
Layoffs
- CollPlant Biotechnologies reported GAAP revenues of $77,000 for Q3 2025 and $2.3 million for the nine months ended September 30, 2025, with the latter including a $2 million milestone payment from AbbVie. The company's GAAP net loss decreased to $3.5 million for Q3 2025 and $8.3 million for the nine months ended September 30, 2025, compared to prior year periods.
- The company has initiated a cost reduction plan, including a 25% workforce reduction, and held $8.5 million in cash and cash equivalents as of September 30, 2025.
- Progress was made in product development, with the AbbVie dermal filler candidate advancing to clinical phase and CollPlant's photocurable dermal filler program entering final preclinical testing. Additionally, CollPlant's rhCollagen was used to create the first fully humanized 3D bioprinted skin model by Mayo Clinic researchers.
- CollPlant is expanding its North American distribution for rhCollagen and BioInk through a new logistics center and commercial leadership. The company also announced that its Board Chairman, Roger Pomerantz, M.D., will not seek re-nomination, with CEO Yehiel Tal nominated as interim Chairman.
Nov 26, 2025, 12:30 PM
CollPlant's Bioink Outperforms Matrigel in Technion Study
CLGN
New Projects/Investments
Product Launch
- CollPlant's rhCollagen-based bioink, Collink.3D™, demonstrated superior performance compared to Matrigel® in a head-to-head study conducted by Technion - Israel Institute of Technology.
- The study highlighted Collink.3D™'s enhanced mechanical strength, elasticity, and stability, suggesting it as a reproducible, animal-free alternative for advanced tissue engineering and research applications.
- The global market for basement membrane matrices, which includes products like Matrigel, was valued at approximately $96 million in 2024 and is projected to grow to $201 million by 2031 at an 11.2% CAGR.
Oct 20, 2025, 11:00 AM
CollPlant Biotechnologies Announces Development of 3D Bioprinted Human Skin Model by Mayo Clinic Researchers
CLGN
New Projects/Investments
- On October 16, 2025, CollPlant Biotechnologies Ltd. announced that Mayo Clinic researchers developed a first-in-kind fully humanized 3D bioprinted human skin model using CollPlant's proprietary plant-derived recombinant human collagen (rhCollagen) BioInk.
- This innovative model is designed to serve as an alternative to animal testing for preclinical research.
- The platform offers a sustainable and ethical solution with broad potential applications in cosmetic and pharmaceutical testing, disease modeling, and drug development.
- CollPlant's CEO, Yehiel Tal, highlighted the model's significant advantages, including the ability to produce personalized human skin models at scale and reduce animal testing.
Oct 16, 2025, 11:13 AM
Quarterly earnings call transcripts for CollPlant Biotechnologies.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more